Research progress of nitric oxide in Parkinson disease
WANG Linlin1 CHEN Yun2#br#
1.Graduate School, Hubei University of Medicine, Hubei Province, Shiyan 442000, China;
2.Department of Ultrasound, Peking University Shenzhen Hospital, Guangdong Province, Shenzhen 518036, China
Abstract：The main pathological features of Parkinson disease (PD) are the degeneration and disappearance of dopamine neurons in the substantia nigra pars compacta, reduction of dopamine in the striatum and accumulation of abnormally folded α-synuclein in the cytoplasm of residual neurons in the substantia nigra, forms eosinophilic soma-Lewy bodies. Although the pathogenesis of PD is unknown, the main influencing factors are oxidative stress, inflammatory response, and apoptosis. The action characteristics of nitric oxide (NO) at different levels play different physiological and pathological roles in the influencing factors of PD. During the pathogenesis of PD, high levels of NO have pathogenic effects, while low levels of NO have anti-inflammatory, anti-oxidation, and anti-inflammatory responses, thereby playing a role in repair and protection. Based on the role of NO in PD, this article describes the dual role of NO in PD.
[1] Picon-Pages P，Garcia-Buendia J，Munoz FJ. Functions and dysfunctions of nitric oxide in brain [J]. Biochim Biophys Acta Mol Basis Dis，2019，1865（8）：1949-1967.
[2] Solanki K，Rajpoot S，Bezsonov EE，et al. The expanding roles of neuronal nitric oxide synthase （NOS1） [J]. Peer J，2022，10：e13651.
[3] Minhas R，Bansal Y，Bansal G. Inducible nitric oxide synthase inhibitors：A comprehensive update [J]. Med Res Rev，2020， 40（3）：823-855.
[4] Tenopoulou M，Doulias PT. Endothelial nitric oxide synthase-derived nitric oxide in the regulation of metabolism [J]. F1000Res，2020，9：F1000 Faculty Rev-1190.
[5] Paul S，Pan S，Mukherjee A，et al. Nitric Oxide Releasing Delivery Platforms：Design，Detection，Biomedical Applications，and Future Possibilities [J]. Mol Pharm，2021，18（9）：3181-3205.
[6] Bloem BR，Okun MS，Klein C. Parkinson’s disease [J]. Lancet （London，England），2021，397（10291）：2284-2303.
[7] Simon DK，Tanner CM，Brundin P. Parkinson Disease Epidemiology，Pathology，Genetics，and Pathophysiology [J]. Clin Geriatr Med，2020，36（1）：1-12.
[8] Nunes C，Laranjinha J. Nitric oxide and dopamine metabolism converge via mitochondrial dysfunction in the mechanisms of neurodegeneration in Parkinson's disease [J]. Arch Biochem Biophys，2021，704：108877.
[9] Liu Z，Zhou T，Ziegler AC，et al. Oxidative Stress in Neurodegenerative Diseases：From Molecular Mechanisms to Clinical Applications [J]. Oxid Med Cell Longev，2017，2017： 2525967.
[10] 胡安霞，尹昌浩，郭一鸣，等.线粒体功能障碍和氧化应激在帕金森病中的作用[J].医学综述，2021，27（15）：2929-2934.
[11] 张晋毓，田首元，郭志佳，等.铁死亡在神经系统疾病中作用的研究进展[J].中西医结合心脑血管病杂志，2022， 20（23）：4293-4297.
[12] Subedi L，Gaire BP，Parveen A，et al. Nitric Oxide as a Target for Phytochemicals in Anti-Neuroinflammatory Prevention Therapy [J]. Int J Mol Sci，2021，22（9）：4771.
[13] Rauf A，Badoni H，Abu-Izneid T，et al. Neuroinflammatory Markers：Key Indicators in the Pathology of Neurodegenerative Diseases [J]. Molecules （Basel，Switzerland），2022，27（10）：3194.
[14] Rodkin S，Nwosu C，Sannikov A，et al. The Role of Gasotransmitter-Dependent Signaling Mechanisms in Apoptotic Cell Death in Cardiovascular，Rheumatic，Kidney，and Neurodegenerative Diseases and Mental Disorders [J]. Int J Mol Sci，2023，24（7）：6014.
[15] Hendriks KD，Maassen H，van Dijk PR，et al. Gasotransmitters in health and disease：a mitochondria-centered view [J]. Curr Opin Pharmacol，2019，45：87-93.
[16] 何甜，陈缤彬，石清明，等.帕金森病相关分子机制研究进展[J].局解手术学杂志，2022，31（5）：456-460.
[17] Tripathi MK，Kartawy M， Amal H. The role of nitric oxide in brain disorders：Autism spectrum disorder and other psychiatric，neurological，and neurodegenerative disorders [J]. Redox Biol，2020，34：101567.
[18] Tiwari S，Singh S. Reciprocal Upshot of Nitric Oxide，Endoplasmic Reticulum Stress，and Ubiquitin Proteasome System in Parkinson’s Disease Pathology [J]. Neuroscientist，2021，27（4）：340-354.
[19] Ghasemi M，Mayasi Y，Hannoun A，et al. Nitric Oxide and Mitochondrial Function in Neurological Diseases [J]. Neuroscience，2018，376：48-71.
[20] Iova OM，Marin GE，Lazar I，et al. Nitric Oxide/Nitric Oxide Synthase System in the Pathogenesis of Neurodegenerative Disorders-An Overview [J]. Antioxidants （Basel），2023， 12（3）：753.
[21] Chen Y，Yuan S，Cao Y，et al.，Gasotransmitters：Potential Therapeutic Molecules of Fibrotic Diseases [J]. Oxid Med Cell Longev，2021，2021：3206982.
[22] Shefa U，Yeo SG，Kim MS，et al. Role of Gasotransmitters in Oxidative Stresses，Neuroinflammation，and Neuronal Repair [J]. Biomed Res Int，2017，2017：1689341.
[23] L’Episcopo F，Tirolo C，Caniglia S，et al. Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1，2，3，6-tetrahydropyridine model of Parkinson’s disease [J]. J Neuroinflammation，2010，7：83.
[24] Gazzin S，Vitek L，Watchko J，et al. A Novel Perspective on the Biology of Bilirubin in Health and Disease [J]. Trends Mol Med，2016，22（9）：758-768.
[25] Kang IS，Kim RI，Kim C. Carbon Monoxide Regulates Macrophage Differentiation and Polarization toward the M2 Phenotype through Upregulation of Heme Oxygenase 1 [J]. Cells，2021，10（12）：3444.
[26] Li T，Wu C，Fu F，et al. Association between use of aspirin or non-aspirin non-steroidal anti-inflammatory drugs and erectile dysfunction：A systematic review [J]. Medicine，2018， 97（28）：e11367.
[27] Aryal B，Raut BK，Bhattarai S，et al. Potential Therapeutic Applications of Plant-Derived Alkaloids against Inflammatory and Neurodegenerative Diseases [J]. Evid Based Complement Alternat Med，2022，2022：7299778.
[28] Rajesh Y，Kanneganti TD. Innate Immune Cell Death in Neuroinflammation and Alzheimer’s Disease [J]. Cells，2022， 11（12）：1885.
[29] Benhar M. Oxidants，Antioxidants and Thiol Redox Switches in the Control of Regulated Cell Death Pathways [J]. Antioxidants （Basel，Switzerland），2020，9（4）：309.
[30] Ghosh A，Sumi MP，Tupta B，et al.Low levels of nitric oxide promotes heme maturation into several hemeproteins and is also therapeutic [J]. Redox Biol，2022，56：102478.
京公网安备 11010502046598号